4-amino-2-(benzyloxy)benzonitrile | 284044-40-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-amino-2-(benzyloxy)benzonitrile
• 英文别名: 4-amino-2-benzyloxybenzonitrile；4-amino-2-phenylmethoxybenzonitrile
• CAS: 284044-40-2
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: BACKXVWDHDEIHG-UHFFFAOYSA-N

物化性质

• 沸点：
  453.0±35.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-amino-2-(benzyloxy)benzonitrile 在 硫酸 、 水 、 sodium nitrite 作用下， 以52%的产率得到2-(benzyloxy)-4-hydroxybenzonitrile
  参考文献：
  名称：

  Structure−Activity Study of Pentamidine Analogues as Antiprotozoal Agents

  摘要：

  Diamidine 1 (pentamidine) and 65 analogues (2-66) have been tested for in vitro antiprotozoal activities against Trypanosoma brucei rhodesiense, Plasmodium. falciparum, and Leishmania donovani, and for cytotoxicity against mammalian cells. Dications 32, 64, and 66 exhibited antitrypanosomal potencies equal or greater than melarsoprol (IC50 = 4 nM). Nine congeners (2-4, 12, 27, 30, and 64-66) were more active against P. falciparum than artemisinin (IC50 = 6 nM). Eight compounds (12, 32, 33, 44, 59, 62, 64, and 66) exhibited equal or better antileishmanial activities than 1 (IC50 = 1.8 mu M). Several congeners were more active than I in vivo, curing at least 2/4 infected animals in the acute mouse model of trypanosomiasis. The diimidazoline 66 was the most promising compound in the series, showing excellent in vitro activities and high selectivities against T. b. rhodesiense, P. falciparum, and L. donovani combined with high antitrypanosomal efficacy in vivo.

  DOI：

  10.1021/jm801547t
• 作为产物：
  描述：

  2-羟基-4-硝基苯腈 在 盐酸 、 potassium carbonate 、 tin(ll) chloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 生成 4-amino-2-(benzyloxy)benzonitrile
  参考文献：
  名称：

  利用胰蛋白酶样丝氨酸蛋白酶的亚位点S1进行选择性：尿激酶型纤溶酶原激活剂的有效和选择性抑制剂。

  摘要：

  胰蛋白酶样丝氨酸蛋白酶的非选择性抑制剂2-（2-羟基联苯-3-基）-1H-吲哚-5-甲am（1）（Verner，E .; Katz，BA; Spencer，J .; Allen，D 。; Hataye，J .; Hruzewicz，W .; Hui，HC; Kolesnikov，A .; Li，Y .; Luong，C .; Martelli，A .; Radika。K .; Rai，R .; She，M. ； Shrader，W。； Sprengeler，PA； Trapp，S。； Wang，J； Young，WB； Mackman，RLJ Med.Chem.2001，44，2753-2771）已经通过对S1结合的微小结构变化进行了优化。小组提供尿激酶型纤溶酶原激活剂（uPA）的显着选择性和有效抑制剂。包含药物靶标的胰蛋白酶样丝氨酸蛋白酶（1）可以大致分为两个亚家族，即带有Ser190的

  DOI：

  10.1021/jm010244+

文献信息

• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• Exploiting Subsite S1 of Trypsin-Like Serine Proteases for Selectivity:  Potent and Selective Inhibitors of Urokinase-Type Plasminogen Activator
  作者：Richard L. Mackman、Bradley A. Katz、J. Guy Breitenbucher、Hon C. Hui、Erik Verner、Christine Luong、Liang Liu、Paul A. Sprengeler

  DOI：10.1021/jm010244+

  日期：2001.11.1

  2753-2771) has been optimized through minor structural changes on the S1 binding group to afford remarkably selective and potent inhibitors of urokinase-type plasminogen activator (uPA). The trypsin-like serine proteases(1) that comprise drug targets can be broadly categorized into two subfamilies, those with Ser190 and those with Ala190. A single-atom modification, for example, replacement of hydrogen for chlorine

  胰蛋白酶样丝氨酸蛋白酶的非选择性抑制剂2-（2-羟基联苯-3-基）-1H-吲哚-5-甲am（1）（Verner，E .; Katz，BA; Spencer，J .; Allen，D 。; Hataye，J .; Hruzewicz，W .; Hui，HC; Kolesnikov，A .; Li，Y .; Luong，C .; Martelli，A .; Radika。K .; Rai，R .; She，M. ； Shrader，W。； Sprengeler，PA； Trapp，S。； Wang，J； Young，WB； Mackman，RLJ Med.Chem.2001，44，2753-2771）已经通过对S1结合的微小结构变化进行了优化。小组提供尿激酶型纤溶酶原激活剂（uPA）的显着选择性和有效抑制剂。包含药物靶标的胰蛋白酶样丝氨酸蛋白酶（1）可以大致分为两个亚家族，即带有Ser190的
• [EN] TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS<br/>[FR] DERIVES DE TRIAZOLOPYRIMIDINE EN TANT QU'INHIBITEURS DE GLYCOGENE SYNTHASE KINASE 3
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005012307A1

  公开（公告）日：2005-02-10

  This invention concerns a compound of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary arnine and a stereochernic ally isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R1 represents hydrogen; aryl; formyI; Cl.6alkylcarbonyl, C1-6alkyl; C1-6alkyloxycarbonyl; C1-6alkyl substituted with formyl, C1-6alkylearbonyl, C1-­6alkyloxycarbonyl, C1-6alkylcarbonyloxy; or C1-6alkyloxyC1-6alkylcarbonyl optionally substituted with C1-6alkyloxycarbonyl; X represents a direct bond; -(CH2)n3­or -(CH2)m4-X1a-X1b-; R2 represents C3-7cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom. selected from 0, S or N; benzoxazolyl or a radical of formula (a-1), wherein said R2 substituent may optionally be substituted; R3 represents halo; hydroxy; optionally substituted C1-.6alkyl; C2-6a]kenyl or C2-6alkynyl, each optionally substituted; optionally substituted polyhaloC1-6alkyl; optionally substituted C1-6alkyloxy; optionally substituted polyhaloC1-­6alkyloxy; C1-6alkylthio; polyhaloC1-6a]kylthio; C1-6a]kyloxycarbonyl; C1-6alkylcarbonyloxy; C1-6alkylearbonyl; polyhaloC1-6alkylcarbonyl; cyano; carboxyl; aryloxy; arylthio; arylcarbonyl; NR6b R7b; C(=O)-NR 6b R 7b; -NR5-C(=O)R5;'-S(=O)nl-R8a; -NR5S(=O)nl -R 8a;-NR 5 -S(=O)nl -R 8a ; -S-CN; -NR5 -CN;R4 represents hydrogen; halo; hydroxy; optionally substituted C1-4alkyl; C2-4alkenyl or C2-4alkynyl, each optionally substituted; polyha]oC1-3alkyl; optionally substituted C1-4alkyloxy; polyhalo-C1-3alkyloxy; C1-4alkylthio; polyhaloC1-3alkylthio­ C1-4alkyloxycarbonyl; C1-4alkylcarbonyloxy; C1-4alkylcarbonyl; polyhatoC1-4alkyl­carbonyl; nitro; cyano; carboxyl; NR10 R11; C(=O)NR10-R11;NR5-C(=O)-NR10R11;-NR5 -C(=O)-R5; -S(=O)nl,-R12 -NR5-S(=O)nI-R12 ; -S-CN; -NR5 -CN; their use, pharmaceutical compositions comprising them and processes for their preparation.

  这项发明涉及式(I)的化合物，一种N-氧化物，一种药用可接受的加合盐，一种季铵盐和其立体化学异构体形式，其中环A代表苯基、吡啶基、嘧啶基、吡啶并嘧啶基或吡嗪基；R1代表氢；芳基；甲酰基；Cl.6烷基羰基，C1-6烷基；C1-6烷氧羰基；C1-6烷基取代的甲酰基，C1-6烷基羰基，C1-6烷氧羰基，C1-6烷基羰氧基；或C1-6烷氧基C1-6烷基羰基，可选地取代C1-6烷氧羰基；X代表直链键；-(CH2)n3或-(CH2)m4-X1a-X1b-；R2代表C3-7环烷基；苯基；含有至少一个杂原子的4,5,6-或7-成员单环杂环烃，所述杂原子选自O、S或N；苯并噁唑基或式(a-1)的基团，其中所述R2取代基可选择地被取代；R3代表卤素；羟基；可选地取代的C1-6烷基；C2-6烯基或C2-6炔基，每种可选择地被取代；可选择地取代的多卤C1-6烷基；可选择地取代的C1-6烷氧基；可选择地取代的多卤C1-6烷氧基；C1-6烷基硫；多卤C1-6烷基硫；C1-6烷氧羰基；C1-6烷基羰氧基；C1-6烷氧羰基；多卤C1-6烷基羰基；氰基；羧基；芳基氧基；芳基硫；芳基羰基；NR6b R7b；C(=O)-NR 6b R 7b；-NR5-C(=O)R5；'-S(=O)nl-R8a；-NR5S(=O)nl -R 8a；-NR 5 -S(=O)nl -R 8a；-S-CN；-NR5 -CN；R4代表氢；卤素；羟基；可选地取代的C1-4烷基；C2-4烯基或C2-4炔基，每种可选择地被取代；多卤C1-3烷基；可选地取代的C1-4烷氧基；多卤C1-3烷氧基；C1-4烷基硫；多卤C1-3烷基硫；C1-4烷氧羰基；C1-4烷基羰氧基；C1-4烷基羰基；多卤C1-4烷基羰基；硝基；氰基；羧基；NR10 R11；C(=O)NR10-R11；NR5-C(=O)-NR10R11；-NR5 -C(=O)-R5；-S(=O)nl,-R12 -NR5-S(=O)nI-R12；-S-CN；-NR5 -CN；它们的使用，包括它们的药用组合物和其制备方法。
• Acylsulfamide inhibitors of factor VIIa
  申请人：——

  公开号：US20040242585A1

  公开（公告）日：2004-12-02

  Compounds having the general formula I are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties. These compounds may be used in methods of preventing and/or treating clotting disorders. 1

  具有一般化学式I的化合物对抑制丝氨酸蛋白酶酶如组织因子VIIa、因子Xa、凝血酶和激肽酶等具有改进的渗透性能，可用于预防和/或治疗凝血障碍的方法。
• Serine protease inhibitors
  申请人：Genentech, Inc.

  公开号：US20030212071A1

  公开（公告）日：2003-11-13

  Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders. 1

  具有下图所示结构的化合物可用于抑制丝氨酸蛋白酶酶类，如TF / factor VIIa，因子Xa，凝血酶和激肽酶。这些化合物可用于预防和/或治疗凝血障碍的方法。1